



Supplemental Fig. S3. Annual economic benefit per patient from renal dose-adjusted (RDA) dipeptidyl peptidase-4 (DPP4) inhibitors prescription in impaired kidney function (2012 to 2018). The annual cost savings per patient when prescribed RDA DPP4 inhibitors for varying stages of kidney function impairment, measured over the years 2012 to 2018. Panels correspond to patients with estimated glomerular filtration rate (eGFR) (A) <60, (B) <45, and (C) <30 mL/min/1.73 m², respectively, displaying cost trends and savings in models 1 and 2.